Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Suliqua®▼ (Sanofi) is a fixed ratio combination of insulin glargine and lixisenatide licensed for the treatment of adults with type 2 diabetes mellitus.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
Download the full review below to read more.